O papel do papiloma vírus humano nos tumores da cabeça e pescoço
DOI:
https://doi.org/10.34631/sporl.624Palavras-chave:
Papiloma Vírus Humano, tumores da cabeça e pescoço, DNA, álcool, tabacoResumo
A infeção por Papiloma Vírus Humano (HPV) é um dos fatores de risco para o desenvolvimento de tumores da cabeça e pescoço. Pretende-se avaliar a prevalência do HPV nestes tumores em doentes sem hábitos alcoólicos e tabágicos associados.
A presença de DNA do HPV foi testada por PCR (Polymerase Chain Reaction) em todos os doentes com tumor da cabeça e pescoço identificados entre 2010 e 2013. Foram identificados 44 doentes, com média de idades de 61.4 anos, com predomínio do sexo masculino. 6 destes doentes foram DNA-HPV positivo, sendo que 50,0% apresentavam um estadio IV A. 66,7% dos doentes foram submetidos a cirurgia e os restantes a quimio-radioderapia concomitante. A sobrevivência global da população DNA-HPV positiva aos 12 e 60 meses foi de 100% e 50%, respetivamente e da população DNA-HPV negativa de 86.8% e 15.8% respectivamente.
Na nossa população, 13,6% dos doentes apresentaram positividade para DNA – HPV, o que é comparável com estudos publicados.
Referências
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781–89.
Chaturvedi AK, Engels EA, Anderson WF, et al. (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619
Mendenhall WM, Werming JW, Pflister DG (2008) Cancer of Head and Neck: Treatment of Head and Neck Cancers. In: Cancer: Principles and Practice of Oncology, 8th ed. (DeVita, VT, Lawrence, ST & Rosenberg, SA, eds.), pp809–77. Philadelphia: Lippincott, Williams & Wilkins.
D’Souza G, Kreimer AR, Viscidi R, et al. (2007) Case–control study of human
papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944–56.
Al-Awadhi R, Chehadeh W, Kapila K (2011) Prevalence of human papillomavirus among women with normal cervical cytology in Kuwait. J Med Virol. 83(3): 453–460.
World Health Organization (2007) IARC monographs on the evaluation of carcinogenic risks to humans: volume 90 - Human Papillomaviruses. Lyon: International Agency for Research on Cancer.
Shiboski CH, Schmidt BL, Jordan RC (2005) Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 103: 1843–49.
Muñoz N, Bosch FX, de Sanjosé S, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–27.
Bouvard V, Baan R, Straif K, et al (2009) A review of human carcinogens--Part B: biological agents. Lancet Oncol 10:321–322.
Glombitza F, Guntinas-Lichius O, Petersen I (2010) HPV status in head and neck tumors. Pathology –ResearchandPractice 206:229–234.
Deng Z, Hasegawa M, Yamashita Y, et al (2012) Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci 103:2127–2134
Mehanna H, Jones TM, Gregoire V, et al (2012) Oropharyngeal carcinoma related to human papillomavirus. Bmj. 340:c1439
Kumar B et al (2007) Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Phys 69:109-111
Weinberger PM et al (2006) Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 245736-747
Efeyan A, Serrano (2007) M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006–1010.
Lee D, Kwon JH, Kim EH, et al (2010) HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus-positive HeLa cells. Cancer Lett 292:125–132.
Westra WH, Taube JM, Poeta ML, et al (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 14: 366–69.
Michaud WA, Nichols AC, Mroz EA, et al. (2009) Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15: 1645–54.
Kumar B, Cordell KG, Lee JS, et al. (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26: 3128–37.
Goon PK, Stanley MA, Ebmeyer J, et al. (2009). HPV & head and neck cancer: a descriptive update. Head neck oncology 1(1): 36.
Butz K, Geisen C, Ullmann A, et al (1996) Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7- oncogene expression and induction of apoptosis. Int J Cancer 68: 506–13.
Gillison ML, Koch WM, Capone RB, et al. (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709–20.
Liu Y, McKalip A, Herman B (2000) Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation. J Cell Biochem 78: 334–49.
Wierzbicka M, Józefiak A, Jackowska J, et al. (2014) HPV vaccination in head and neck HPV-related pathologies. Otolaryngol Pol 68 (4):157-173.
